Abstract
The elucidation of the triggering molecular mechanism of chronic myeloid leukemia gave rise to the development of imatinib, a tyrosine kinase inhibitor and a prototype of target-oriented drugs. Imatinib led to impressing response and survival rates and now represents the standard therapy of CML. However, a significant proportion of patients do not tolerate or fail to respond to imatinib treatment. Alternative therapies can be offered to those patients. The particular challenge of CML patient management is to recognize an impending imatinib failure by adequate surveillance and to know about therapeutic options to prevent progression of the disease to accelerated phase or blast crisis since these are more difficult to control. Targeted therapy with second-generation tyrosine kinase inhibitors should be used in synopsis with mutational analysis and the patients history. In this review we present current knowledge of diagnosis, monitoring and therapy strategies of patients with CML.
Keywords: Chronic myeloid leukemia, imatinib, dasatinib, nilotinib, BCR-ABL, mutation, rare disease, diagnosis, lymphoblastic, fatigue, weight loss, abdominal discomfort, splenomegaly, myeloproliferative neoplasm (MPN), polycythemia vera, thrombocythemia, Leukemia Virus, hematopoietic cells, blood counts, complete hematologic remission (CHR), malignant cells, histologic, cytologic, White blood cell count, fluorescence, hybridization (FISH), metaphases, Plasma Leve, intestinal absorption, metabolism, glycoprotein, hydroxyurea, arsenic, splenectomy, splenic irradiation, busulfan, pregnancy, ribonucleotide, tyrosine kinase inhibitors (TKI), antimetabolite cytarabine, monotherapy, autophosphorylation, bioavailability, phosphate-binding, nucleotide polymorphisms, DOSE, potency, pharmacokinetics, first line therapy, lymphoid, blood-brain barrier, toxicity, Stem Cell Transplantation (SCT), autologous SCT, chemotherapy, diabetes, electrocardiograms
Current Cancer Drug Targets
Title: Current Treatment Concepts of CML
Volume: 11 Issue: 1
Author(s): A. A. Leitner, A. Hochhaus and M. C. Muller
Affiliation:
Keywords: Chronic myeloid leukemia, imatinib, dasatinib, nilotinib, BCR-ABL, mutation, rare disease, diagnosis, lymphoblastic, fatigue, weight loss, abdominal discomfort, splenomegaly, myeloproliferative neoplasm (MPN), polycythemia vera, thrombocythemia, Leukemia Virus, hematopoietic cells, blood counts, complete hematologic remission (CHR), malignant cells, histologic, cytologic, White blood cell count, fluorescence, hybridization (FISH), metaphases, Plasma Leve, intestinal absorption, metabolism, glycoprotein, hydroxyurea, arsenic, splenectomy, splenic irradiation, busulfan, pregnancy, ribonucleotide, tyrosine kinase inhibitors (TKI), antimetabolite cytarabine, monotherapy, autophosphorylation, bioavailability, phosphate-binding, nucleotide polymorphisms, DOSE, potency, pharmacokinetics, first line therapy, lymphoid, blood-brain barrier, toxicity, Stem Cell Transplantation (SCT), autologous SCT, chemotherapy, diabetes, electrocardiograms
Abstract: The elucidation of the triggering molecular mechanism of chronic myeloid leukemia gave rise to the development of imatinib, a tyrosine kinase inhibitor and a prototype of target-oriented drugs. Imatinib led to impressing response and survival rates and now represents the standard therapy of CML. However, a significant proportion of patients do not tolerate or fail to respond to imatinib treatment. Alternative therapies can be offered to those patients. The particular challenge of CML patient management is to recognize an impending imatinib failure by adequate surveillance and to know about therapeutic options to prevent progression of the disease to accelerated phase or blast crisis since these are more difficult to control. Targeted therapy with second-generation tyrosine kinase inhibitors should be used in synopsis with mutational analysis and the patients history. In this review we present current knowledge of diagnosis, monitoring and therapy strategies of patients with CML.
Export Options
About this article
Cite this article as:
A. Leitner A., Hochhaus A. and C. Muller M., Current Treatment Concepts of CML, Current Cancer Drug Targets 2011; 11 (1) . https://dx.doi.org/10.2174/156800911793743637
DOI https://dx.doi.org/10.2174/156800911793743637 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
Novel Therapeutic Approaches to Target Drug Resistant Tumors
With the development of disciplines such as chemical biology and molecular biology, the genes or proteins closely related to tumor occurrence and development have gradually become clear. Targeted therapies targeting these genes or proteins provide more effective methods for tumor treatment. Tumor targeted drugs generally only act on specific targets ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Revisiting the ABCs of Multidrug Resistance in Cancer Chemotherapy
Current Pharmaceutical Biotechnology Synthetic Peptides As Non-Viral DNA Vectors
Current Gene Therapy Molecules of Parasites as Immunomodulatory Drugs
Current Topics in Medicinal Chemistry Protein Phosphatase Inhibition: Structure Based Design. Towards New Therapeutic Agents
Current Pharmaceutical Design 5-Nitro-Thiophene-Thiosemicarbazone Derivatives Present Antitumor Activity Mediated by Apoptosis and DNA Intercalation
Current Topics in Medicinal Chemistry The Influence of Lipophilicity on the Classification of Antitumor Acridinones Evaluated by Principal Component Analysis
Current Pharmaceutical Analysis Nonviral Vectors for Cancer Gene Therapy: Prospects for Integrating Vectors and Combination Therapies
Current Gene Therapy Vitamin D and Lung Cancer
Current Respiratory Medicine Reviews Interferon-Alpha in the Treatment of Multiple Myeloma
Current Drug Targets Signal Transduction Pathways and Transcription Factors as Therapeutic Targets in Inflammatory Disease: Towards Innovative Antirheumatic Therapy
Current Pharmaceutical Design Determination of Three Tyrosine Kinase Inhibitors and One Active Metabolite by an Identical and Validated Ultra-performance Liquid Chromatography-DAD Method in Human Plasma
Current Pharmaceutical Analysis Proteolytic Cleavage of Notch: “HIT and RUN”
Current Molecular Medicine NBN Polymorphysms and Cancer Susceptibility: A Systematic Review
Current Genomics Interferon-Beta Therapy Monitoring in Multiple Sclerosis Patients
Endocrine, Metabolic & Immune Disorders - Drug Targets Alternative Splicing in Chronic Myeloid Leukemia (CML): A Novel Therapeutic Target?
Current Cancer Drug Targets Bioactive Compounds Containing Benzoxadiazole, Benzothiadiazole, Benzotriazole
Current Bioactive Compounds Chemomodulating Effects of Flavonoids in Human Leukemia Cells
Anti-Cancer Agents in Medicinal Chemistry Tipping the Balance Between Life and Death: Targeting Histone Acetylation for Cancer Therapy
Drug Delivery Letters The Epidermal Growth Factor Receptor as a Therapeutic Target in Glioblastoma Multiforme and other Malignant Neoplasms
Anti-Cancer Agents in Medicinal Chemistry Mechanisms Involved in Apoptosis Events Contributing to Sepsis-Induced Myocardial Dysfunction
Current Drug Therapy